50612-99-2

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-Bromo-2-(4-Methoxyphenyl)acetate is used as an intermediate in the synthesis of Ambucetamide (A575935) for its role in creating an effective antispasmodic medication. Ambucetamide is particularly effective in providing relief from menstrual pain, making it a valuable compound in the development of treatments for dysmenorrhea.

Upstream product

• 23786-14-3 4-methoxy-phenyl acetic acid methyl ester 
• 67-56-1 methanol 
• 17478-44-3 α-bromo-4-methoxyphenylacetic acid 
• 104-01-8 4-Methoxyphenylacetic acid 

Downstream Products

• 53119-84-9 (4-Methoxy-phenyl)-[methyl-(toluene-4-sulfonyl)-amino]-acetic acid methyl ester 
• 113791-16-5 (S)-(4-Methoxy-phenyl)-((S)-2-oxo-3-phenylacetylamino-azetidin-1-yl)-acetic acid methyl ester 
• 113791-15-4 methyl D-2-(3-phenylacetamido-2-oxo-1-azetidinyl)-2-(4-methoxyphenyl)acetate 
• 32191-59-6 (3-Methoxy-phenoxy)-(4-methoxy-phenyl)-acetic acid methyl ester 
• 32191-55-2 (4-Methoxy-phenyl)-m-tolyloxy-acetic acid methyl ester 
• 32191-53-0 methyl 2-phenoxy-2-(4-methoxyphenyl)acetate 
• 551929-13-6 (4-methoxy-phenyl)-[2-(4-methoxy-phenyl)-1,3-dioxo-indan-2-yl]-acetic acid methyl ester 
• 682356-51-0 [5-methoxy-2-(4-methoxy-phenyl)-1,3-dioxo-indan-2-yl]-(4-methoxy-phenyl)-acetic acid methyl ester 
• 253328-37-9 2-(p-methoxyphenyl)ethanol-1,1,2-d3 
• 682356-45-2 [5-methoxy-2-(4-methoxy-phenyl)-1,3-dioxo-indan-2-yl]-(4-methoxy-phenyl)-acetic acid 
• 551929-16-9 C₂₅H₂₂O₂ 
• 551929-14-7 (4-methoxy-phenyl)-[2-(4-methoxy-phenyl)-indan-2-yl]-acetic acid 
• 551929-15-8 C₂₅H₂₂O₃ 
• 551929-20-5 C₂₆H₂₄O₂ 

Relevant academic research and scientific papers

Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions

Nuclear factor erythroid 2-related factor 2 (NRF2) is a pleiotropic transcription factor which regulates the constitutive and inducible transcription of a wide array of genes and confers protection against a variety of pathologies. Directly disrupting Kelch-like ECH-associated protein 1 (KEAP1)-NRF2 protein-protein interaction (PPI) has been explored as a promising strategy to activate NRF2. We reported here the first identification of a series of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 inhibitors. Our efforts led to the potent small molecule KEAP1-NRF2 inhibitor, 20c, which exhibited a Kd of 24 nM to KEAP1 and an IC50 of 75 nM in disrupting KEAP1-NRF2 interaction. Subsequent biological studies provided consistent evidence across mouse macrophage cell-based and in vivo models that 20c induced NRF2 target gene expression and enhanced downstream antioxidant and anti-inflammatory activities. Our study not only demonstrated that small molecule KEAP1-NRF2 PPI inhibitors can be potential preventive and therapeutic agents for diseases and conditions involving oxidative stress and inflammation but also enriched the chemical diversity of the KEAP1-NRF2 inhibitors.

Structure-activity relationships study of neolamellarin A and its analogues as hypoxia inducible factor-1 (HIF-1) inhibitors

The novel marine pyrrole alkaloid neolamellarin A derived from sponge has been shown to inhibit hypoxia-induced HIF-1 activity. In this work, we designed and synthesized neolamellarin A and its series of derivatives by a convergent synthetic strategy. The HIF-1 inhibitory activity and cytotoxicity of these compounds were evaluated in Hela cells by dual-luciferase reporter gene assay and MTT assay, respectively. The results showed that neolamellarin A 1 (IC50 = 10.8 ± 1.0 μM) and derivative 2b (IC50 = 11.9 ± 3.6 μM) had the best HIF-1 inhibitory activity and low cytotoxicity. Our SAR research focused on the effects of key regions aliphatic carbon chain length, aromatic ring substituents and C-7 substituent on biological activity, providing a basis for the subsequent research on the development of novel pyrrole alkaloids as HIF-1 inhibitors and design of small molecule probes for target protein identification.

Total synthesis and application of natural product of 7-hydroxy novel lamellarin A and analogues of natural product of 7-hydroxy novel lamellarin A

The invention belongs to the technical field of pharmaceutical and chemical engineering, and provides total synthesis and application of a natural product of 7-hydroxy novel lamellarin A and analoguesof the natural product of the 7-hydroxy novel lamellarin A. The invention provides the 7-hydroxy novel lamellarin A natural product and the series of analogues of the 7-hydroxy novel lamellarin A natural product. Tested compounds all have medium to good HIF-1 inhibitory activity, and have no market toxicity under the effective inhibition concentration of HIF-1 of the tested compounds, and it is indicated that the compounds have the potential for treating cancers by inhibiting transcription activating of the HIF-1.

Diastereo- And Enantioselective Synthesis of Quaternary α-Amino Acid Precursors by Copper-Catalyzed Propargylation

A diastereo- and enantioselective propargylic substitution reaction between propargylic carbonates and α-substituted nitroacetates catalyzed by a Cu-pybox complex is described. This method allows the preparation of a series of non-proteinogenic quaternary α-amino acid precursors featuring two contiguous stereogenic centers and a terminal alkyne moiety in high yields with good to excellent diastereo- and enantioselectivities in most cases. The propargylated adducts were elaborated into a diverse set of quaternary α-amino acid derivatives.

Development and evaluation of ST-1829 based on 5-benzylidene-2-phenylthiazolones as promising agent for anti-leukotriene therapy

Different inflammatory diseases and allergic reactions are mediated by leukotrienes, which arise from the oxygenation of arachidonic acid catalyzed by 5-lipoxygenase (5-LO). One promising approach for an effective anti-leukotriene therapy is the inhibition of this key enzyme. This study presents the synthesis and development of a potent and direct 5-LO inhibitor based on the well characterized 5-benzylidene-2-phenylthiazolone C06, whose further pharmacological investigation was precluded due to its low solubility. Through optimization of C06, evaluation of structure-activity relationships including profound assessment of the thiazolone core and consideration of the solubility, the 5-benzyl-2-phenyl-4-hydroxythiazoles represented by 46 (ST-1829, 5-(4-chlorobenzyl)-2-p-tolylthiazol-4-ol) were developed. Compound 46 showed an improved 5-LO inhibitory activity in cell-based (ICinf50/inf values 0.141/4M) and cell-free assays (ICinf50/inf values 0.03 1/4M) as well as a prominent enhanced solubility. Furthermore, it kept its promising inhibitory potency in the presence of blood serum, excluding excessive binding to serum proteins. These facts combined with the non-cytotoxic profile mark a major step towards an effective anti-inflammatory therapy.

Synthesis of Quinolines by Visible-Light Induced Radical Reaction of Vinyl Azides and α-Carbonyl Benzyl Bromides

A visible-light induced radical reaction of vinyl azides and α-carbonyl benzyl bromides was developed, which provides an efficient route to polysubstituted quinolines via a C-C and C-N bond formation sequence.

1, 3, 4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER

The specification relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.

MINERALOCORTICOID RECEPTOR ANTAGONISTS

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophyl

Total synthesis of dictyodendrins A-E

A highly efficient total synthesis of dictyodendrins A-E was accomplished. The synthesis features a novel benzyne-mediated one-pot indoline formation/cross-coupling sequence for the construction of a highly substituted key indoline intermediate. Peripheral substituents were introduced onto this intermediate in a modular fashion to complete the total synthesis of dictyodendrins A-E. A benzyne-mediated one-pot indoline formation/cross-coupling sequence is used for the construction of a highly substituted common indole intermediate. The peripheral substituents were introduced using a Friedel-Crafts reaction on the indole intermediate in a modular fashion to complete the total synthesis. Copyright

Carbon-carbon bond-forming reactions of α-carbonyl carbocations: Exploration of a reversed-polarity equivalent of enolate chemistry

Carbon-carbon bond-forming reactions of putative α-carbonyl carbocation intermediates generated by Lewis acid- or silver-promoted ionizations of toluenesulfonate or halide leaving groups are described. This under-exploited mode of reactivity represents an 'umpolung' of conventional enolate chemistry, and enables C-C bond construction in both intra- and intermolecular contexts. Attempts to develop diastereoselective variants of this process using chiral ester and oxazolidinone-based auxiliaries are discussed.